Zealand Pharma

Copenhagen, 2015-11-04 17:00 CET (GLOBE NEWSWIRE) -- Copenhagen, 4 November
2015 – Zealand announces that its share capital has been increased by nominal
DKK 60,843 divided into 60,843 new shares with a nominal value of DKK 1 each.
The increase is a consequence of the exercise of employee warrants granted
under one of the company's warrant programs as described in the Articles of
Association.

The exercise price is DKK 94.60 per share for 60,843 of the new shares. The
total proceeds to Zealand from the capital increase amounts to DKK
5,755,747.80.

The new shares give rights to dividend and other rights from the time of the
warrant holder's exercise notice. Each new share carries one vote at Zealand’s
general meetings. Zealand only has one class of shares.

The new shares will be listed on Nasdaq Copenhagen following registration of
the capital increase with the Danish Business Authority. Following registration
of the new shares, the share capital of Zealand will be nominal DKK 24,112,843
divided into 24,112,843 shares with a nominal value of DKK 1 each.

The amendment of Zealand’s Articles of Association entailed by the share
capital increase has today been registered with the Danish Business Authority.
The new Articles of Association are attached to this announcement and are also
available on the company’s website: www.zealandpharma.com.

The content of this announcement has no impact on the company’s financial
guidance for 2015.

Pursuant to Section 28a of the Danish Securities Trading Act, Zealand discloses
information on transactions with the company’s shares and related
securities by executives and their related parties. In connection with the
warrants exercise, Zealand has received information on the following
transaction for disclosure:

Name: Mats Blom

Reason: Senior Vice President and Chief Financial Officer (CFO)

Issuer: Zealand Pharma A/S

Designation: Shares

ISIN Code: DK0060257814

Transaction: Exercise of warrants

Trading Date: 4 November 2015

Market: Nasdaq OMX Copenhagen A/S

Number: 60,843

Price: DKK 94.60

Market value: DKK 5,755,747.80

                                  ?????

For further information, please contact:

Hanne Leth Hillman, Senior Vice President for Investor Relations and
Communications
Tel: +45 50 60 36 89, email: [email protected]

About Zealand Pharma
Zealand Pharma A/S (Nasdaq Copenhagen: ZEAL) (“Zealand”) is a medicinal biotech
company with leading expertise in the identification, design and development of
novel peptide medicines. Zealand has a proprietary pipeline of novel drug
candidates and a portfolio of products and projects under license
collaborations with Sanofi, Helsinn Healthcare and Boehringer Ingelheim –
primarily in the fields of cardio-metabolic diseases and acute care
indications.

The proprietary pipeline includes; danegaptide for ischemic reperfusion
Injuries in Phase II development, ZP1848 for Short Bowel Syndrome in Phase II
development and the stable glucagon analogue, ZP4207 as a single-dose rescue
pen for severe hypoglycemia in preparation for Phase II, and ZP4207 as
multiple-dose use for the correction of mild to moderate hypoglycemia in
evaluation for the next clinical development step after Phase I, as well as
several preclinical peptide therapeutics.

Zealand has invented lixisenatide, a once-daily prandial GLP-1 agonist, which
is marketed globally (ex-US) by Sanofi for the treatment of Type 2 diabetes and
since end September 2015 has been under review by the FDA in the US. The
license agreement with Sanofi also covers a fixed-ratio combination of
lixisenatide and insulin glargine (Lantus®) which is on track for regulatory
submission in the US in Q4 2015 and in Europe in Q1 2016.

The company is based in Copenhagen (Glostrup), Denmark. For further information
about Zealand’s business and activities, please visit: www.zealandpharma.com or
follow us on Twitter @ZealandPharma

AI Terminal